MeCure Industries Plc has opened an offer of up to N14 billion Series 8 Commercial Paper under its N40 billion Commercial Paper Programme.
The Lagos-based manufacturer of medicines and multivitamins has been using the market to raise money for its short-term working capital needs.
This offer carries an implied annual yield of 21%. Investors holding the paper for its full 267-day duration would earn approximately 15.36% on the amount invested, before applicable deductions, provided MeCure repays in full.
The offer opened on Wednesday, October 14, 2026, and closes on Tuesday, October 20, 2026.
The issuance follows MeCure’s offer of up to N10 billion Series 7 commercial paper in February 2026, which carried a 269-day tenor and a gross annualised yield of 21.75%.
On N5 million actually invested, the stated annualised yield would generate about N768,000 in gross income over 267 days, using a 365-day calculation basis.
Total proceeds would be approximately N5.768 million, before applicable deductions and subject to full repayment.
MeCure’s 21% annual yield is higher than the 17.16% and 18.91% offered by six-month and one-year Treasury bills at the October 14 auction.
MeCure’s announcement that it fully repaid its N3 billion bond in April 2026 offers some reassurance about its ability to honour debt obligations.
Its growing business provides further support. Revenue increased 20.4% to N44.85 billion in H1 2026, while lower marketing expenses helped operating profit rise faster, by 41% to N10.90 billion.
MeCure’s operating profit still covered these costs, but they took a larger share of its earnings despite the growth in the business.
The new facilities could help reverse that trend if they generate enough additional sales and cash to outpace the associated costs. For CP investors, repayment confidence will depend on those cash receipts and the funding available when the paper matures.
The offer provides a gross annualised yield of 21%, equivalent to approximately 15.36% over 267 days.
Investors should confirm net income after applicable deductions and plan around the July 2027 maturity.
The principal considerations are rising financing costs, cash committed to expansion and the timing of customer receipts.
Sustained cash generation and a clear repayment funding plan would provide additional reassurance alongside MeCure’s earnings growth and stated credit ratings.
